… Rituximab has been shown to be safe and effective in the treatment of non-renal SLE, …
We also excluded specific articles about lupus nephritis, cutaneous lupus erythematosus or …

… This article summarizes the SLR of the prevalence and treatment of neuropsychiatric and
other non-renal manifestations of SLE, with a special focus on Asian studies. Overall, there is a …

… treated with MMF for non‐renal indications, the toxicity profile of MMF in SLE is derived mainly
from studies in lupus … effects of MMF in 73 lupus nephritis patients reported in uncontrolled …

… had lupus nephritis, and the remaining 61 patients had non-renal SLE … therapy in improving
some of the objective parameters that we routinely use to monitor renal and non-renal lupus …

… therapy in non-renal lupus in terms of prevention of flares iii) clarify risks of longterm
immunosuppressive therapy… for withdrawal of glucocorticoid or immunosuppressive therapy; and …

… Several of the immunosuppressants analyzed demonstrated their efficacy and safety in the
treatment of nonrenal SLE with a steroid-sparing effect. Our systematic review demonstrated …

… in adult patients with active SLE despite standard of care (4). Here we report one case with
severe non-renal SLE that developed nephritis on belimumab treatment. Oral and written …

… treatment of non-renal manifestations of the disease. In spite of that, several of those
manifestations are frequently treated … in the treatment of non-renal systemic lupus erythematosus (…

… non-renal lupus activity remains controversial. Our objective was to identify non-renal,
non-neurologic persistent active systemic lupus … All systemic lupus erythematosus patients (…

… We enrolled all the SLE patients in which MMF treatment was prescribed in our Lupus Clinic
according to the standard of care. Thus, we analyzed 162 patients [M/F 22/140; median age …